Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

doi:10.1038/s41598-021-81176-w

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 化妝品應用與管理系(所) > 期刊論文 > Item 310902800/34496

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34496

標題:	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
作者:	Chu, Shou-Sheng Kuo, Yu-Hsuan Liu, Wen-Shan Wang, Shih-Chang Ho, Chung-Han Chen, Yi-Chen Yang, Ching-Chieh Wu, Hung-Chang
貢獻者:	Chi Mei Med Ctr, Dept Radiat Oncol Chi Mei Med Ctr, Dept Hematol & Oncol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Kaohsiung Vet Gen Hosp, Dept Radiat Oncol Meiho Univ, Dept Nursing Natl Def Med Ctr, Sch Med Antai Med Care Corp Antai Tian Sheng Mem Hosp, Dept Radiat Oncol Chi Mei Med Ctr, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chia Nan Univ Pharm & Sci, Dept Pharm
關鍵字:	RADIATION-THERAPY OUTCOMES CIRRHOSIS PATTERNS PHASE-2
日期:	2021
上傳時間:	2023-11-11 11:58:33 (UTC+8)
出版者:	NATURE PORTFOLIO
摘要:	Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy. The study cohort included 4763 patients with diagnosed advanced HCC who received sorafenib between January 2012 and December 2015, as reported in medical records in the Taiwan Cancer Registry database. The effect of sorafenib with or without radiotherapy on survival was calculated using the Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazards model was used for multivariate analysis. Patients receiving sorafenib plus radiotherapy had greater 1-year survival than did those receiving sorafenib alone (P<0.001). Uni- and multivariate analyses also showed that radiotherapy increased survival after adjusting for confounders (adjusted HR 0.57; 95% CI 0.51-0.63). Further stratified analysis according to the timing of radiotherapy relative to sorafenib treatment revealed that patients who underwent radiotherapy after sorafenib had greater 1-year survival than did those undergoing radiotherapy within sorafenib use or sorafenib alone (adjusted HR 0.39; 95% CI 0.27-0.54). Combined treatment with sorafenib and radiotherapy results in greater HCC patient survival and should be considered an option for treating this challenging disease.
關聯:	SCI REP-UK, v.11, n.1, pp.1614
顯示於類別:	[化妝品應用與管理系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	194	檢視/開啟
s41598-021-81176-w.pdf		1135Kb	Adobe PDF	94	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....